Private Health Insurance Medical Devices Human Tissue Products Rules No. 2 2026
Summary
Australia's Department of Health, Disability and Ageing has promulgated the Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2026, a legislative instrument that came into force on 24 April 2026. The rules govern the coverage and reimbursement arrangements for medical devices and human tissue products under private health insurance contracts. As a federal legislative instrument administered by the department, this rule sets binding requirements for private health insurers operating in Australia.
“Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2026”
About this source
This feed tracks every Australian federal legislative instrument registered on the Federal Register of Legislation in the last 7 days. Legislative instruments are how Australian federal regulators (ASIC, APRA, ACCC, the TGA, AUSTRAC, the ATO, and dozens of departmental delegates) actually make and amend rules between Acts of Parliament. Around 220 instruments a month, ranging from narrow scarcity declarations to scheme-wide rule rewrites. GovPing publishes each as soon as it lands on legislation.gov.au. Watch this if you advise on Australian financial services, therapeutic goods, AML, consumer credit, or any sector where the substantive rules live in delegated legislation rather than primary statute. Recent: an ASIC instrument on serviced apartment schemes, a TGA scarcity declaration on clonidine.
What changed
The Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2026 establishes a new regulatory framework governing the types, standards, and reimbursement conditions for medical devices and human tissue products covered under private health insurance policies. The instrument applies to all private health insurers and registered health benefits managers operating in Australia.
Private health insurers must ensure their coverage terms, claim processing procedures, and contractual arrangements with providers align with the device and tissue product standards specified in this legislative instrument. Healthcare providers supplying medical devices or human tissue products to privately insured patients should verify that their products and services meet the requirements set out in this instrument to ensure eligible reimbursement.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
- Interactions
Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 2) 2026
In force Administered by
- Department of Health, Disability and Ageing
Latest version F2026L00449 24 April 2026
View document Legislative instrument Filter active Table of contents
- Volume 1
- Volume 2
- Volume 3
Related changes
Get daily alerts for AU Federal Legislative Instruments (7-day)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from DoH AU.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when AU Federal Legislative Instruments (7-day) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.